Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Sarissa Capital Management urges Amarin shareholders to vote the BLUE proxy card ahead of the general meeting on February 28, 2023. Shareholders should ensure their votes are submitted by February 21, 2023. Sarissa's presentation highlights inaccuracies in Amarin's statements aimed at protecting its board, advocating for the election of Sarissa’s nominees and the removal of Chairman Per Wold-Olsen. Shareholders are encouraged to refrain from using Amarin’s WHITE proxy card, with additional details available on Sarissa's website and through its proxy solicitor, D.F. King & Co., Inc.
Amarin Corporation (NASDAQ: AMRN) sent a letter to shareholders urging them to vote "AGAINST" Sarissa Capital's proposals during the upcoming General Meeting set for February 28, 2023. The company criticized Sarissa for spreading misleading information and attempting to take control of the board with underqualified nominees. Key points include Sarissa's historical negative impact on shareholder value, with a median total shareholder return of -24% at companies with Sarissa-nominated directors. Amarin emphasizes its commitment to maximizing shareholder value and has initiated cost-saving measures, achieving $50 million in reductions in 2022.
Sarissa Capital Management has launched a dedicated website for Amarin Corporation shareholders, emphasizing the importance of voting with the BLUE proxy card by February 21, 2023, at 11:59 PM EST. The proxy card will allow shareholders to support Sarissa's slate of nominees at Amarin's upcoming general meeting on February 28, 2023. Sarissa advises against using Amarin’s WHITE proxy card. Shareholders can access important documents via the SEC website or Sarissa's site for further instructions on voting and to view their presentation.
Amarin Corporation plc (NASDAQ: AMRN) urges shareholders to vote against all proposals by Sarissa Capital Management at the upcoming General Meeting on February 28, 2023. The company emphasizes its newly appointed Board, led by Chairman Per Wold-Olsen, is executing a transformative strategy to enhance shareholder value. Key achievements include securing six international regulatory approvals in 2022, stabilizing U.S. revenue for four consecutive quarters, and implementing a $100 million annual cost savings plan. Amarin's leadership asserts that Sarissa’s proposed changes could jeopardize the company's progress.
Sarissa Capital Management is urging Amarin Corporation (NASDAQ: AMRN) shareholders to support their nominees for the board and remove Chairman Per Wold-Olsen at the upcoming general meeting on February 22, 2023. They emphasize the 64% stock decline in 2022, which resulted in over $840 million lost in shareholder value due to alleged mismanagement. Sarissa argues that adding their nominees will help maximize shareholder value based on their successful track record in the healthcare sector. They contend that the current leadership is obstructing accountability and shareholder representation, further advocating for the vote before key deadlines.
Amarin Corporation plc (NASDAQ: AMRN) has filed definitive proxy materials with the SEC for its upcoming General Meeting on February 28, 2023. Shareholders are urged to vote "AGAINST" Sarissa Capital Management's proxy proposals, arguing that Sarissa lacks a constructive plan and has presented an underqualified slate of nominees. Over the past 18 months, Amarin has revamped its leadership and board, focusing on geographic expansion and enhancing operational efficiency. The company is confident in achieving up to $1 billion in revenue opportunities through its strategies, despite facing generic competition in the U.S.
Amarin Corporation (NASDAQ: AMRN) announced that Medsafe in New Zealand has granted regulatory approval for VAZKEPA (icosapent ethyl) to reduce cardiovascular (CV) event risks in statin-treated adults with high CV risk and elevated triglycerides. This marks the seventh approval for the VASCEPA/VAZKEPA franchise in key international markets since 2022. Cardiovascular disease significantly impacts New Zealand, with about 175,000 adults affected. Amarin is now seeking commercialization partners to support VAZKEPA's introduction in New Zealand.
Amarin Corporation plc (NASDAQ:AMRN) announced that CEO Karim Mikhail will participate in the SVB Securities Global Biopharma Conference, scheduled for February 14, 2023, at 10:40 a.m. ET. This virtual conference will span from February 13-16, 2023. The presentation will be available via webcast and will be archived on the company's website.
Amarin focuses on cardiovascular disease management and is committed to advancing treatment options.
Amarin Corporation plc (NASDAQ:AMRN) responds to Sarissa Capital's intervention, highlighting a comprehensive and independent board refreshment process. Amarin emphasizes its recognition of shareholder frustration due to U.S. IP losses and outlines a new strategy alongside a revamped management team. The board has successfully negotiated pricing for VAZKEPA® in five European markets and has secured six international regulatory approvals. Despite facing generic competition, Amarin maintains approximately 60% market share, a competitive advantage in the industry. The company aims to continue stabilizing revenue and advancing its fixed-dose combination program.
Sarissa Capital Management has expressed deep concern over Amarin's board governance, highlighting the absence of shareholder representation. In 2022, Amarin's stock plummeted by over two-thirds, translating to a loss of more than $840 million in equity for its shareholders. Key issues include delays in the European launch, challenges in securing reimbursement in Germany, and ineffective management responses that led to significant capital destruction. Sarissa, as Amarin's largest shareholder, is pushing for a special meeting to remove Chairman Per Wold-Olsen and appoint new directors to enhance shareholder interests.